New & Notable
FDA reminds sponsors, researchers to report clinical trial results
As part of its ongoing push for greater transparency, the FDA is seeking voluntary compliance from thousands of clinical trial sponsors and investigators, reminding them to publicly publish findings within one year of trial completion.
Lilly boosts ADC portfolio with CrossBridge Bio deal
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
— BioPharma Dive
Will RFK Jr.’s peptide push bolster the gray market for obesity drugs?
With competition fierce in the weight loss space, a potential change to how the FDA classifies peptides could increase pressure in the market even more.
— PharmaVoice
Amazon Pharmacy adds Lilly's obesity pill with same-day delivery
Amazon's pharmacy now sells Eli Lilly's recently approved weight loss pill at in-office kiosks and offers same-day delivery online.
Trump revives pharma tariffs with 100% charges, but leaves loopholes
— BioPharma DiveFDA approves Lilly obesity pill, triggering battle with Novo Nordisk
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
GLP-1 drugs show promise in managing chronic migraines
Chronic migraine patients taking GLP-1s are associated with fewer ER visits, hospitalizations and treatment interventions than those taking a common first-line migraine drug, a study shows.
-
Boehringer Ingelheim adds 3 drugs to TrumpRx
Boehringer Ingelheim is the latest drugmaker to make good on its TrumpRx deal with the White House, expanding the self-pay platform's offerings by three more medications.
-
Lilly's triple-G agonist shows unique promise in late-stage diabetes trial
Eli Lilly's experimental triple hormone agonist, retatrutide, helped patients with type 2 diabetes lower blood sugar by up to 2% and lose up to 16.8% of their weight in a phase 3 study.
-
Roche's new NVIDIA deal locks in the industry's 'largest hybrid-cloud AI factory'
Roche is expanding its global AI infrastructure to deploy a large-scale AI factory powered by NVIDIA's latest-generation accelerated computing stack to speed up drug and diagnostics development.
-
Structure's GLP-1 pill shows 'injectable-like efficacy' in a mid-stage obesity study
Structure Therapeutics' GLP-1 pill, aleniglipron, triggered up to 16.2% continued weight loss in a phase 2 obesity trial, reaffirming its "best in class" potential.
-
Lilly warns of impurities in compounded tirzepatide containing B12
Eli Lilly says compounded tirzepatide products mixed with vitamin B12 have been found to form impurities that could pose safety risks.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.